Bausch Health Exceeds Q2 Expectations, Raises Full-Year Guidance

Bausch Health Companies Inc. (BHC) announced its financial results for the second quarter of 2026, significantly surpassing analyst expectations and subsequently raising its full-year financial guidance. The company reported its thirteenth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth, excluding Bausch + Lomb, highlighting sustained operational strength and portfolio resilience. This consistent performance reflects the company's strategic execution and the dedication of its global teams.

For the second quarter, consolidated revenues climbed to $2.85 billion, marking a 13% increase year-over-year (11% on an organic basis), comfortably beating the Zacks Consensus Estimate of $2.65 billion. Adjusted earnings per diluted share (EPS) surged by 40% year-over-year to $1.26, substantially exceeding the consensus estimates ranging from $0.96 to $0.99. Adjusted EBITDA, excluding Bausch + Lomb, also saw a robust increase of 28%, reaching $1.075 billion. Key segments demonstrated strong contributions, with Salix revenue growing 21%, primarily driven by Xifaxan, and Solta Medical reporting a 38% increase in reported revenue (12% organic), boosted by significant growth in the China market.

In addition to strong top-line performance, Bausch Health continued its focus on financial deleveraging. The company reduced its net debt by $434 million during the quarter, bringing the total to approximately $13.7 billion. This reduction represents one of the largest since its 2022 debt refinancing. Thomas J. Appio, CEO of Bausch Health, noted that this performance enhances financial flexibility and supports ongoing investments in the business, its pipeline, and future development opportunities.

Following the impressive earnings report, Bausch Health's stock (BHC) experienced a significant rally, gaining over 27% the day after the announcement. Jean-Jacques Charhon, the company's Chief Financial Officer, indicated that he believes the stock remains undervalued at its current level. The market's positive reaction underscores investor confidence in the company's operational momentum and enhanced profitability.

The company is navigating a complex external environment, including potential impacts from the U.S. Inflation Reduction Act on Xifaxan pricing, which are expected to take effect in 2027, as well as uncertainties related to potential retaliatory trade measures and tariffs. However, management has stated that the updated full-year 2026 guidance already incorporates the anticipated effects of new pharmaceutical tariffs slated for late September 2026.

Looking ahead, analysts and market participants are closely monitoring Bausch Health's raised full-year 2026 guidance. The company now projects consolidated revenues between $10.8 billion and $11.0 billion (up from $10.7 billion - $10.9 billion), Adjusted EBITDA between $4.1 billion and $4.2 billion (up from $3.9 billion - $4.0 billion), and Adjusted Cash Flows from Operations between $1.400 billion and $1.475 billion. Despite potential headwinds, management remains confident in driving long-term value creation and sustaining its positive momentum.